Abcam

Abcam PLC

Type	Public company
Traded as	LSE: ABC
Industry	Biotech, Life sciences
Founded	1998
Key people	Alan Hirzel CEO
Products	Research antibodies, kits and assays for biological research
Revenue	£144.0m (2015)
Profit	£49.6m (2015)
Number of employees	> 820 (2015)
Website	www.abcam.com

Abcam plc is a global "life science tools provider" based in the Cambridge Science Park in Cambridge, UK, with offices in Cambridge (Massachusetts, US), San Francisco, Hong Kong, Shanghai, and Tokyo. As of 2015, the company's chief executive officer was Alan Hirzel.

History

The idea for the company originated in the University of Cambridge laboratory, UK in 1998. The principal founder Jonathan Milner was a postdoctoral researcher studying the newly discovered breast cancer protein BRCA2 in Professor Tony Kouzarides' laboratory. The project slowed because of problems finding quality antibody reagents that had honest and up-to-date information about their uses and limitations. This scenario provided the motivation to form an on-line service that would help themselves and researchers across the globe.

Since its inception in 1998, the company has diversified from carrying only antibodies. It supplies antibody related products such as immunoassays (e.g. SimpleStep ELISA Kits), peptides, proteins and protein detection products (e.g. immunohistochemistry (IHC) staining kits. Abcam also has a portfolio of non-antibody related products such as biochemicals, cellular assays, and epigenetics kits (e.g. Firefly Multiplex miRNA Kits).

Abcam is a life-science e-commerce company which facilitates public customer feedback on products using reviews and ratings submitted by customers. This has given rise to the nickname "the Amazon of antibodies".

Abcam is listed on the London Stock Exchange.

Acquisitions

In May 2011, Abcam announced the acquisition of MitoSciences, a privately held biotech company based in Eugene, Oregon (US). The company produced and distributed immunoassay platforms and high performance monoclonal antibodies. It was founded in 2004 with the mission of advancing mitochondrial research and developing products that support critical research in cancer, neurodegeneration, and metabolic disorders.

On 12 September 2011, Abcam completed the purchase of Ascent Scientific. Ascent Scientific was a company based in Bristol, United Kingdom that provided high-quality biochemical products that modulate the function of proteins for use in life science research.

On 19 April 2012, Abcam completed the purchase of Epitomics. Epitomics was a privately held biotech company in San Francisco, California (US) and Hangzhou (China) that focused on the development, production, and distribution of rabbit monoclonal antibodies for biomedical research and diagnostic applications.

On 20 January 2015, Abcam announced the acquisition of Firefly BioWorks, a privately held company based in Cambridge, Massachusetts (US), for GB£18.5 million. Firefly developed a novel multiplex assay platform for the detection of biomarkers, based on a microfabrication technology developed by Davide Marini and Daniel Pregibon at Massachusetts Institute of Technology, and launched its first products for the multiplex detection of microRNA from RNA and crude biofluid.

On 11 November 2015, Abcam announced the acquisition of AxioMx. AxioMx, based in Branford, Connecticut (US), "provides a comprehensive custom recombinant antibody discovery and development services platform".

External links

• Abcam website
• Browse all Abcam antibody products, application images and publications at SeekProducts from SeekQuence
• Cambridge Network profile